{
    "references": [
        {
            "bibentry": "Siegel, R, DeSantis, C, Virgo, K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220–41. PMID: 22700443",
            "process_entry": "True",
            "doi": "10.3322/caac.21149",
            "pmid": "22700443",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30. PMID: 29313949",
            "process_entry": "True",
            "doi": "10.3322/caac.21442",
            "pmid": "29313949",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Tannus, RK, Almeida-Carvalho, SR, Loureiro-Matos, CA, et al. Evaluation of survival of patients with hepatocellular carcinoma: a comparative analysis of prognostic systems. PLoS One 2018; 13: e0194922. PMID: 29617435",
            "process_entry": "True",
            "doi": "10.1371/journal.pone.0194922",
            "pmid": "29617435",
            "pmcid": "PMC5884519",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Zhuang, H, Jiang, W, Cheng, W, et al. Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. Lung Cancer 2010; 68: 27–38. PMID: 19540014",
            "process_entry": "True",
            "doi": "10.1016/j.lungcan.2009.05.014",
            "pmid": "19540014",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Jin, K, Yin, H, De Clercq, E, et al. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. Eur J Med Chem 2018; 145: 726–34. PMID: 29353724",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.01.016",
            "pmid": "29353724",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Bai, S, Liu, S, Zhu, Y, Wu, Q. Asymmetric synthesis and antiviral activity of novel chiral amino-pyrimidine derivatives. Tetrahedron Lett 2018; 59: 3179–83.",
            "process_entry": "True",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Madhu Sekhar, M, Nagarjuna, U, Padmavathi, V, et al. Synthesis and antimicrobial activity of pyrimidinyl 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles. Eur J Med Chem 2018; 145: 1–10. PMID: 29310025",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.12.067",
            "pmid": "29310025",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Rizk, SA, El-Naggar, AM, El-Badawy, AA. Synthesis, spectroscopic characterization and computational chemical study of 5-cyano-2-thiouracil derivatives as potential antimicrobial agents. J Mol Struct 2018; 1155: 720–33.",
            "process_entry": "True",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Saleeb, M, Sundin, C, Aglar, O, et al. Structure-activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity. Eur J Med Chem 2018; 143: 568–76. PMID: 29207339",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.11.036",
            "pmid": "29207339",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Borik, RM, Fawzy, NM, Abu-Bakr, SM, Aly, MS. Design, synthesis, anticancer evaluation and docking studies of novel heterocyclic derivatives obtained via reactions Involving curcumin. Molecules 2018; 23: 1398.",
            "process_entry": "True",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Abdelgawad, MA, Bakr, RB, Azouz, AA. Novel pyrimidine-pyridine hybrids: synthesis, cyclooxygenase inhibition, anti-inflammatory activity and ulcerogenic liability. Bioorg Chem 2018; 77: 339–48. PMID: 29421710",
            "process_entry": "True",
            "doi": "10.1016/j.bioorg.2018.01.028",
            "pmid": "29421710",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Mohamed, MS, Youns, MM, Ahmed, NM. Synthesis, antimicrobial, antioxidant activities of novel 6-aryl-5-cyano thiouracil derivatives. Eur J Med Chem 2013; 69: 591–600. PMID: 24095752",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2013.08.032",
            "pmid": "24095752",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Awad, SM, Zohny, YM, Ali, SA, et al. Design, synthesis, molecular modeling, and biological evaluation of novel thiouracil derivatives as potential antithyroid agents. Molecules 2018; 23: 2913.",
            "process_entry": "True",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Sahu, M, Siddiqui, N, Sharma, V, Wakode, S. 5,6-Dihydropyrimidine-1(2H)-carbothioamides: synthesis, in vitro GABA-AT screening, anticonvulsant activity and molecular modelling study. Bioorg Chem 2018; 77: 56–67. PMID: 29331765",
            "process_entry": "True",
            "doi": "10.1016/j.bioorg.2017.12.031",
            "pmid": "29331765",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Jha, V, Bhadoriya, KS. Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents. J Mol Struct 2018; 1158: 96–105.",
            "process_entry": "True",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Santi, DV, McHenry, CS, Sommer, H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471–81. PMID: 4203910",
            "process_entry": "True",
            "doi": "10.1021/bi00700a012",
            "pmid": "4203910",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Pastor, N, Dominguez, I, Orta, ML, et al. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res 2012; 738–739: 45–51.",
            "process_entry": "True",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Cooper, MR, Chim, H, Chan, H, Durand, C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother 2015; 49: 107–12. PMID: 25258420",
            "process_entry": "True",
            "doi": "10.1177/1060028014553619",
            "pmid": "25258420",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Chan, WY, Lau, PM, Yeung, KW, Kong, SK. The second-generation tyrosine kinase inhibitor dasatinib induced eryptosis in human erythrocytes-An in vitro study. Toxicol Lett 2018; 295: 10–21. PMID: 29803841",
            "process_entry": "True",
            "doi": "10.1016/j.toxlet.2018.05.030",
            "pmid": "29803841",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "El-Mezayen, NS, El-Hadidy, WF, El-Refaie, WM, et al. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis. J Control Release 2017; 266: 226–37. PMID: 28965860",
            "process_entry": "True",
            "doi": "10.1016/j.jconrel.2017.09.035",
            "pmid": "28965860",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Tang, B, Tang, P, He, J, et al. Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: insights from spectroscopic, calorimetric and docking studies. J Photochem Photobiol B Biol 2018; 184: 18–26.",
            "process_entry": "True",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Wilson, GS, Tian, A, Hebbard, L, et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett 2013; 341: 224–30. PMID: 23941832",
            "process_entry": "True",
            "doi": "10.1016/j.canlet.2013.08.009",
            "pmid": "23941832",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Shaker, ME, Ghani, A, Shiha, GE, et al. Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim Biophys Acta 2013; 1833: 1992–2003. PMID: 23499874",
            "process_entry": "True",
            "doi": "10.1016/j.bbamcr.2013.02.033",
            "pmid": "23499874",
            "pmcid": "PMC5410771",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "He, J, Ma, L, Wei, Z, et al. Synthesis and biological evaluation of novel pyrazoline derivatives as potent anti-inflammatory agents. Bioorg Med Chem Lett 2015; 25: 2429–33. PMID: 25881822",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2015.03.087",
            "pmid": "25881822",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Shubhalaxmi Pathak, L, Ananda, K, Bhat, KS. Synthesis of focused library of novel aryloxyacids and pyrazoline derivatives: molecular docking studies and antimicrobial investigation. Cogent Chem 2016; 2: 1141388.",
            "process_entry": "True",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "P. James, J, Ishwar Bhat, K, More, UA, Joshi, SD. Design, synthesis, molecular modeling, and ADMET studies of some pyrazoline derivatives as shikimate kinase inhibitors. Med Chem Res 2018; 27: 546–59.",
            "process_entry": "True",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Ramaswamy, B, Mrozek, E, Kuebler, JP, et al. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Invest New Drugs 2011; 29: 347–51. PMID: 19844661",
            "process_entry": "True",
            "doi": "10.1007/s10637-009-9338-1",
            "pmid": "19844661",
            "pmcid": "PMC3486428",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Ranieri, G, Mammi, M, Donato Di Paola, E, et al. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol 2014; 89: 322–9. PMID: 24041629",
            "process_entry": "True",
            "doi": "10.1016/j.critrevonc.2013.08.012",
            "pmid": "24041629",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Na, JI, Na, JY, Choi, WY, et al. The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model. Am J Transl Res 2015; 7: 751–60. PMID: 26064442",
            "process_entry": "True",
            "pmid": "26064442",
            "pmcid": "PMC4455349",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "George, DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res 2007; 13: 753s–7s. PMID: 17255305",
            "process_entry": "True",
            "doi": "10.1158/1078-0432.ccr-06-2044",
            "pmid": "17255305",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Abd-Rabou, AA, Abdel-Wahab, BF, Bekheit, MS. Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1,2,3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents. Chem Pap 2018; 72: 2225–37.",
            "process_entry": "True",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Xu, W, Pan, Y, Wang, H, et al. Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents in hepG-2 cell line. Molecules 2017; 22:pii: E467. PMID: 28300751",
            "process_entry": "True",
            "doi": "10.3390/molecules22030467",
            "pmid": "28300751",
            "pmcid": "PMC6155299",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Sangthong, S, Ha, H, Teerawattananon, T, et al. Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives. Bioorg Med Chem Lett 2013; 23: 6156–60. PMID: 24095089",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2013.09.004",
            "pmid": "24095089",
            "xmlid": "CIT0033"
        },
        {
            "bibentry": "Kraicheva, I, Vodenicharova, E, Shenkov, S, et al. Synthesis, characterization, antitumor activity and safety testing of novel polyphosphoesters bearing anthracene-derived aminophosphonate units. Bioorg Med Chem 2014; 22: 874–82. PMID: 24365391",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2013.12.001",
            "pmid": "24365391",
            "xmlid": "CIT0034"
        },
        {
            "bibentry": "Pavitha, P, Prashanth, J, Ramu, G, et al. Synthesis, structural, spectroscopic, anti-cancer and molecular docking studies on novel 2-[(Anthracene-9-ylmethylene) amino]-2-methylpropane-1,3-diol using XRD, FTIR, NMR, UV–Vis spectra and DFT. J Mol Struct 2017; 1147: 406–26.",
            "process_entry": "True",
            "xmlid": "CIT0035"
        },
        {
            "bibentry": "Cutts, SM, Nudelman, A, Rephaeli, A, Phillips, DR. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005; 57: 73–81. PMID: 16036566",
            "process_entry": "True",
            "doi": "10.1080/15216540500079093",
            "pmid": "16036566",
            "xmlid": "CIT0036"
        },
        {
            "bibentry": "Xie, SQ, Zhang, ZQ, Hu, GQ, et al. HL-37, a novel anthracene derivative, induces Ca (2+)-mediated apoptosis in human breast cancer cells. Toxicology 2008; 254: 68–74. PMID: 18948164",
            "process_entry": "True",
            "doi": "10.1016/j.tox.2008.09.021",
            "pmid": "18948164",
            "xmlid": "CIT0037"
        },
        {
            "bibentry": "Mohamed, MS, Awad, SM, Ahmed, NM. Synthesis and antimicrobial evaluation of some 6-aryl-5-cyano-2-thiouracil derivatives. Acta Pharm 2011; 61: 171–85. PMID: 21684845",
            "process_entry": "True",
            "doi": "10.2478/v10007-011-0019-1",
            "pmid": "21684845",
            "xmlid": "CIT0038"
        },
        {
            "bibentry": "Marella, A, Akhter, M, Shaquiquzzaman, M, et al. Synthesis, 3D-QSAR and docking studies of pyrimidine nitrile-pyrazoline: a novel class of hybrid antimalarial agents. Med Chem Res 2015; 24: 1018–37.",
            "process_entry": "True",
            "xmlid": "CIT0039"
        },
        {
            "bibentry": "Taher, AT, Helwa, AA. Novel pyrimidinone derivatives: synthesis, antitumor and antimicrobial evaluation. Chem Pharm Bull (Tokyo) 2012; 60: 521–30. PMID: 22466736",
            "process_entry": "True",
            "doi": "10.1248/cpb.60.521",
            "pmid": "22466736",
            "xmlid": "CIT0040"
        },
        {
            "bibentry": "Aqlan, FMS, Makki, MST, Abdel-Rahman, RM. Synthesis, spectroscopic studies of fluorinated pyrimido-1,2,4-triazines: protective effect against some plant pathogenic fungi. J Heterocycl Chem 2016; 53: 1310–7.",
            "process_entry": "True",
            "xmlid": "CIT0041"
        },
        {
            "bibentry": "Mohamed, MS, Awad, SM, Ahmed, NM. Synthesis and antimicrobial activities of new indolyl-pyrimidine derivatives. J Appl Pharm Sci 2011; 1: 76–80.",
            "process_entry": "True",
            "xmlid": "CIT0042"
        },
        {
            "bibentry": "Mohamed, MS, Ahmed, NM. Synthesis, characterization and study of antimicrobial activity of some novel 5-cyano-2-thiouracil derivatives. Int J Pharm Sci 2014; 4: 591–600.",
            "process_entry": "True",
            "xmlid": "CIT0043"
        },
        {
            "bibentry": "Prabhakar, M, Merry, T, Tsurho, S, et al. Synthesis, characterization and biological evaluation of 9-anthracenyl chalcones as anti-cancer agents. J Chem Pharm Res 2017; 9: 185–92.",
            "process_entry": "True",
            "xmlid": "CIT0044"
        },
        {
            "bibentry": "Nasr, T, Bondock, S, Youns, M. Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur J Med Chem 2014; 76: 539–48. PMID: 24607878",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2014.02.026",
            "pmid": "24607878",
            "xmlid": "CIT0045"
        },
        {
            "bibentry": "Riedl, SJ, Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897–907. PMID: 15520809",
            "process_entry": "True",
            "doi": "10.1038/nrm1496",
            "pmid": "15520809",
            "xmlid": "CIT0046"
        },
        {
            "bibentry": "Abdallah, MA, Gomha, SM, Morad, MA, Elaasser, MM. Synthesis of pyridotriazolopyrimidines as antitumor agents. J Heterocycl Chem 2017; 54: 1242–51.",
            "process_entry": "True",
            "xmlid": "CIT0047"
        },
        {
            "bibentry": "Abbas, I, Gomha, S, El-Neairy, M, et al. Synthesis and biological evaluation of novel fused triazolo[4,3-a] pyrimidinones. Turk J Chem 2015; 39: 510–31.",
            "process_entry": "True",
            "xmlid": "CIT0048"
        },
        {
            "bibentry": "Frederick, CA, Williams, LD, Ughetto, G, et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990; 29: 2538–49. PMID: 2334681",
            "process_entry": "True",
            "doi": "10.1021/bi00462a016",
            "pmid": "2334681",
            "xmlid": "CIT0049"
        }
    ],
    "localid": "MED-31117890",
    "doi": "10.1080/14756366.2019.1612889",
    "pmid": "10.1080/14756366.2019.1612889",
    "pmcid": "31117890",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31117890/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,91)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),553,111)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0003",
                "rp_string": "3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),666,152)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1042,94)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 5,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 6,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 8,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 9,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 10,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 13,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 14,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),90,268)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[12]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 16,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[13]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 17,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[14]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 18,
                "xref_id": "CIT0019",
                "rp_string": "19",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[15]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 19,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[16]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 20,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[17]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 21,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[18]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 22,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[19]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),434,714)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrimidine ring is one of the mostly used heterocyclic scaffolds in medicinal chemistry. Pyrimidine derivatives have been well recognised for their therapeutic applications i.e. antiviral5,6, antibacterial7,8, antifungal9, anti-inflammatory10, COX-2 inhibitors11, antioxidant12, antithyroid13, anticonvulsant14, and anti-diabetic15. Pyrimidine ring is also an integral part of DNA nucleic acid composition. Various drugs containing pyrimidine nucleus are being used as potent anticancer agents through different mechanisms of action i.e. 5-Fluorouracil® (5-FU) I as thymidylate synthase inhibitor16, Merbarone®II as DNA topoisomerase II (topoII) catalytic inhibitor17, Ceritinib (LDK378) III as anaplastic lymphoma kinase (ALK) inhibitor18, Dasatinib IV as multi-targeted of Bcr-Abl and Src family kinases inhibitor apoptosis inducer19, Imatinib V as a receptor tyrosine kinase (TKI) inhibitor20, Ibrutinib (IBR) VI as Bruton’s tyrosine kinase (BTK) inhibitor21, Ruxolitinib (INC424) VII as Janus kinase (JAK) inhibitor22 and Nilotinib VIII as tyrosine kinase inhibitor and apoptosis inducer23 (Figure 1).",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,218)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 24,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,218)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 25,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,218)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0027",
                "rp_string": "27",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),221,300)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 27,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),221,300)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 28,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),221,300)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 29,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),221,300)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Pyrazoline ring is another widely used heterocyclic nucleus in medicinal chemistry because of its wide spectrum of pharmacological activities i.e. anti-inflamatory24, antibacterial25, and antioxidant26 activities. Many pyrazoline derivatives was found to have anticancer activity against various human cancer types with different mode of action i.e. Pyrazoloacridine (PZA) (IX)27, Axitinib (AG013736) (X)28, Pazopanib (GW786034) (XI)29 and 3–(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) (XII)30. New pyrazoline derivatives XIII and XIV were reported as potential anticancer agents in hepatic HepG2 cancer cell line and induced HepG2 cells apoptosis 31,32 (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0031",
                "rp_string": "31",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),523,175)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0033",
                "rp_string": "33–35",
                "pl_string": "33–35",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),96,334)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 32,
                "xref_id": "",
                "pl_string": "33–35",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),96,334)",
                "containers_title": [
                    "Introduction"
                ]
            },
            {
                "n_rp": 33,
                "xref_id": "",
                "pl_string": "33–35",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),96,334)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0033",
                "rp_string": "33–35",
                "pl_string": "33–35",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "pl_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),96,334)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 35,
                "xref_id": "CIT0038",
                "rp_string": "38",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[1]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[1]/p),1,79)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitriles (1a-e)"
                ]
            }
        ],
        [
            {
                "n_rp": 36,
                "xref_id": "CIT0039",
                "rp_string": "39",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-2-hydrazinyl-4-oxo-1,4-dihydropyrimidine-5-carbonitriles (2a-e)"
                ]
            }
        ],
        [
            {
                "n_rp": 37,
                "xref_id": "CIT0040",
                "rp_string": "40",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-2-hydrazinyl-4-oxo-1,4-dihydropyrimidine-5-carbonitriles (2a-e)"
                ],
                "pl_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),31,11)",
                "pl_string": "b\n40\n\n,\n\n41"
            },
            {
                "n_rp": 38,
                "xref_id": "CIT0041",
                "rp_string": "41",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-2-hydrazinyl-4-oxo-1,4-dihydropyrimidine-5-carbonitriles (2a-e)"
                ],
                "pl_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),31,11)",
                "pl_string": "b\n40\n\n,\n\n41"
            }
        ],
        [
            {
                "n_rp": 39,
                "xref_id": "CIT0042",
                "rp_string": "42",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-2-hydrazinyl-4-oxo-1,4-dihydropyrimidine-5-carbonitriles (2a-e)"
                ]
            }
        ],
        [
            {
                "n_rp": 40,
                "xref_id": "CIT0043",
                "rp_string": "43",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[2]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[2]/p[1]),1,117)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "6-Aryl-2-hydrazinyl-4-oxo-1,4-dihydropyrimidine-5-carbonitriles (2a-e)"
                ]
            }
        ],
        [
            {
                "n_rp": 41,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[2]/sec[2]/sec[3]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/sec[3]/p),1,81)",
                "containers_title": [
                    "Materials and methods",
                    "Chemistry",
                    "(2E)-1–(9-anthryl)-3- substituted prop-2-en-1-ones (3a-d)"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0045",
                "rp_string": "45",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,406)",
                "containers_title": [
                    "Materials and methods",
                    "In vitro cytotoxicity activity"
                ]
            }
        ],
        [
            {
                "n_rp": 43,
                "xref_id": "CIT0045",
                "rp_string": "45",
                "rp_xpath": "/article/body/sec[2]/sec[4]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/p),1,209)",
                "containers_title": [
                    "Materials and methods",
                    "Caspase-Glo 3/7 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 44,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[2]/sec[5]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[5]/p),1,171)",
                "containers_title": [
                    "Materials and methods",
                    "Molecular modelling procedure"
                ]
            }
        ],
        [
            {
                "n_rp": 45,
                "xref_id": "CIT0038",
                "rp_string": "38",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),111,215)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0040",
                "rp_string": "40",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),328,197)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 47,
                "xref_id": "CIT0046",
                "rp_string": "46",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),161,84)",
                "containers_title": [
                    "Results and discussion",
                    "Caspase 3/7 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 48,
                "xref_id": "CIT0045",
                "rp_string": "45",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),247,167)",
                "containers_title": [
                    "Results and discussion",
                    "Caspase 3/7 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 49,
                "xref_id": "CIT0047",
                "rp_string": "47",
                "rp_xpath": "/article/body/sec[3]/sec[3]/p/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[3]/p),416,174)",
                "containers_title": [
                    "Results and discussion",
                    "Caspase 3/7 assay"
                ]
            }
        ],
        [
            {
                "n_rp": 50,
                "xref_id": "CIT0049",
                "rp_string": "49",
                "rp_xpath": "/article/body/sec[3]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[4]/p),462,226)",
                "containers_title": [
                    "Results and discussion",
                    "Molecular modelling"
                ]
            }
        ]
    ]
}